Gemphire's gemcabene meets in Phase IIb for severe hypertriglyceridemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported data from the Phase IIb INDIGO-1 trial to treat severe hypertriglyceridemia showing that once-daily 600 mg oral gemcabene (CI-1027) met the primary endpoint of reducing median triglycerides from baseline to week 12 vs. placebo (47% vs. 27%, p=0.0063). The company said it is finalizing Phase III plans for the candidate.

On secondary endpoints, gemcabene led to significant, median placebo-adjusted reductions of 24% in LDL-C, 16% in non-HDL-C, 19% in VLDL-C and 12% in apolipoprotein B (APOB) from baseline to week 12 (p<0.05 for all)...